Peptide Therapy Market

Peptide therapy refers to restoring the amount of peptides to stimulate the cellular regeneration system in the body, and can be an excellent complement to small molecule and biotherapeutics as a treatment option under certain conditions. The most common uses of peptide therapy are to help build muscle and reduce fat, increase energy, improve sexual function, and reduce gastrointestinal and musculoskeletal inflammation. The most common prescription peptide combinations naturally boost growth hormone for better recovery. Peptides were initially used only for diagnostics and hormone therapy; however, as technology has advanced, they are now also widely used to treat cancer and chronic metabolic diseases. Peptides are also used in cosmeceutical operations to slow down the skin's aging process.

Peptide Therapy Market contains market size and forecasts of Peptide Therapy in global, including the following market information:

Global Peptide Therapy Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Peptide Therapy Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Peptide Therapy companies in 2021 (%)

The global Peptide Therapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Parenteral Route of Administration Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Peptide Therapy include Eli Lilly, AstraZeneca, Merck, Ipsen, Novo Nordisk, Teva Pharmaceutical Industries, Abbott Laboratories, Sanofi and J & J, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Peptide Therapy manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Peptide Therapy Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Peptide Therapy Market Segment Percentages, by Type, 2021 (%)

Parenteral Route of Administration

Mucosal Route of Administration

Oral Route of Administration

Transdermal Route of Administration

Global Peptide Therapy Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Peptide Therapy Market Segment Percentages, by Application, 2021 (%)

Cancer

Cardiovascular Diseases

Gastrointestinal Disorders

Metabolic Disorders

Others

Global Peptide Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Peptide Therapy Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Peptide Therapy revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Peptide Therapy revenues share in global market, 2021 (%)

Key companies Peptide Therapy sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Peptide Therapy sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Eli Lilly

AstraZeneca

Merck

Ipsen

Novo Nordisk

Teva Pharmaceutical Industries

Abbott Laboratories

Sanofi

J & J

Novartis

Takeda

Ferring

AbbVie

Heinis

Hemmo

Emcure Pharmaceutical

Cipla

Gland Pharma

Troikaa Pharmaceuticals

Biological E